Join Growin Stock Community!

竟天6917.TW Overview

TW StockBiotech. & Medical
(No presentation for 6917)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

竟天（6917）Overall Performance

竟天（6917）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

竟天（6917） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

竟天（6917）Key Information

竟天（6917）Profile

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.

竟天（6917）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.90
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1168.58
PB Ratio
3.26
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
30.86%
Net Margin
-16065.63%
Revenue Growth (YoY)
-93.36%
Profit Growth (YoY)
-96.78%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.90
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1168.58
PB Ratio
3.26
Price-to-FCF
-
Gross Margin
30.86%
Net Margin
-16065.63%
Revenue Growth (YoY)
-93.36%
Profit Growth (YoY)
-96.78%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6917

竟天

21.10D

-5.21%

(-0.05)

  • When is 6917's latest earnings report released?

    The most recent financial report for 竟天 (6917) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6917's short-term business performance and financial health. For the latest updates on 6917's earnings releases, visit this page regularly.

  • How much cash does 6917 have?

    At the end of the period, 竟天 (6917) held Total Cash and Cash Equivalents of 32.9M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6917 go with three margins increasing?

    In the latest report, 竟天 (6917) did not achieve the “three margins increasing” benchmark, with a gross margin of 3.13%%, operating margin of -63,025%%, and net margin of -72,259.38%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6917's profit trajectory and future growth potential.